---
title: "JFL Life Sciences Ltd (JFLLIFE) — Share Price, Financials & Analysis"
symbol: "JFLLIFE"
company: "JFL Life Sciences Ltd"
canonical: "https://tapetide.com/stocks/JFLLIFE"
isin: "INE0LA901015"
nse_symbol: "JFLLIFE"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 70.28
generated_at: "2026-09-13T19:38:08.165Z"
---

# JFL Life Sciences Ltd (JFLLIFE)

Canonical page: https://tapetide.com/stocks/JFLLIFE

## Company

- **NSE Symbol:** JFLLIFE
- **ISIN:** INE0LA901015
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2022-09-08
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** jfllifesciences.com

## About

Incorporated in 2010, JFL Life Sciences Ltd produces and markets a wide range of formulations[1]

## Latest Price

- **Price:** ₹10.65
- **Change:** 0 (0%)
- **Open:** ₹10.65
- **Day High:** ₹10.65
- **Day Low:** ₹10.65
- **Previous Close:** ₹10.65
- **Volume:** 0
- **As Of:** 2026-09-11T10:01:44+00:00

## Key Fundamentals

Observed at 2026-09-11T04:47:24.967151Z.

- **Market Cap:** ₹70.28 Cr
- **Classification:** SME
- **P/E (reported):** 5.2
- **P/E (TTM):** 10.34
- **EPS (TTM):** ₹1.03
- **Book Value:** ₹13.9
- **Price to Book:** 0.77
- **Dividend Yield:** 2.35%
- **ROE:** 10.54%
- **ROCE:** 17.91%
- **Debt to Equity:** 0.48
- **Revenue (yearly):** ₹131.38 Cr
- **Net Income:** ₹6.44 Cr
- **EBITDA:** ₹11.71 Cr
- **52-Week High:** ₹15.4
- **52-Week Low:** ₹8.55
- **RSI (14):** 46.3

## Tapetide Score

- **Score:** 59 / 100
- **Score date:** 2026-09-04
- **Archetype:** No Dominant Pattern
- **What it means:** The three pillars do not combine into a recognisable pattern. Read them individually rather than looking for one story — the lack of a pattern is itself the finding.
- **Pillar profile:** Quality: Average · Valuation: Cheap · Momentum: Falling
- **Percentile:** 84.7 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 36.74 | 9% |
| growth | 94.25 | 9% |
| momentum | 41.6 | 12% |
| ownership | 50 | 24% |
| quality | 50.44 | 22% |
| valuation | 74.42 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter
- Company has delivered good profit growth of 64.0% CAGR over last 5 years
- Company's working capital requirements have reduced from 136 days to 103 days

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.2% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -142.22% | 61.08% | 39.86% |
| ebitda margin growth | -41.67% | -10.9% | -17.73% | -50.85% |
| net income growth | -35.29% | 53.33% | 32% | 64% |
| revenue growth | -82.41% | 60.02% | 45% | 32% |
| roce | — | 38.94% | 17.91% | 17.71% |
| roe | — | 13.58% | 9.51% | 33.59% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 21.7 | 9.54 | 39.51 | 21.25 | 11.73 | 11.59 | 29.91 | 26.84 | 63.05 | 11.1 |
| Expenses | 20.15 | 6.48 | 37.1 | 19.9 | 10.35 | 9.66 | 27 | 23.49 | 59.54 | 9.01 |
| Operating Profit | 1.55 | 3.06 | 2.41 | 1.35 | 1.38 | 1.93 | 2.91 | 3.35 | 3.51 | 2.09 |
| OPM % | 7.14 | 32.08 | 6.1 | 6.35 | 11.76 | 16.65 | 9.73 | 12.48 | 5.57 | 18.83 |
| Other Income | 0.02 | 0 | 0 | 0 | 0 | 0 | 0.01 | 0.01 | 0.04 | 0.02 |
| Interest | 0.09 | 0.26 | 0.27 | 0.2 | 0.33 | 0.24 | 0.44 | 0.38 | 1.03 | 0.3 |
| Depreciation | 0.11 | 0.24 | 0.24 | 0.16 | 0.36 | 0.26 | 0.27 | 0.27 | 0.27 | 0.32 |
| Profit before tax | 1.37 | 2.56 | 1.9 | 0.99 | 0.69 | 1.43 | 2.21 | 2.71 | 2.25 | 1.49 |
| Tax % | 13.14 | 25.39 | 23.16 | 25.25 | 86.96 | 48.25 | 10.86 | 25.09 | 26.22 | 25.5 |
| Net Profit | 1.19 | 1.91 | 1.45 | 0.74 | 0.08 | 0.75 | 1.97 | 2.02 | 1.66 | 1.11 |
| EPS in Rs | 0.18 | 0.29 | 0.22 | 0.11 | 0.01 | 0.11 | 0.3 | 0.31 | 0.25 | 0.17 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 32 | 30 | 33 | 34 | 43 | 47 | 82 | 131 | 131 |
| Expenses | 30 | 28 | 31 | 28 | 39 | 42 | 74 | 120 | 119 |
| Operating Profit | 1 | 2 | 2 | 5 | 4 | 5 | 8 | 12 | 12 |
| OPM % | 4.2 | 6 | 7 | 16 | 9 | 10 | 10 | 9 | 9 |
| Other Income | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 0 | 0 | 1 | 4 | 4 | 4 | 6 | 9 | 9 |
| Tax % | 28 | 29 | 27 | 26 | 25 | 13 | 32 | 26 | — |
| Net Profit | 0 | 0 | 1 | 3 | 3 | 3 | 4 | 6 | 7 |
| EPS in Rs | 1.25 | 1.5 | 1.5 | 0.59 | 0.43 | 0.5 | 0.63 | 0.97 | 1.03 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.42 | 0.42 | 0.5 | 8 | 11 | 11 | 33 | 33 |
| Reserves | 5 | 5 | 6 | 3 | 21 | 25 | 6 | 13 |
| Borrowings | 8 | 9 | 17 | 16 | 7 | 6 | 11 | 22 |
| Other Liabilities | 3 | 10 | 5 | 21 | 10 | 15 | 22 | 39 |
| Total Liabilities | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |
| Fixed Assets | 2 | 5 | 6 | 7 | 7 | 12 | 12 | 15 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 14 | 19 | 23 | 41 | 42 | 44 | 60 | 92 |
| Total Assets | 16 | 24 | 29 | 48 | 49 | 57 | 72 | 106 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -3 | 3 | -6 | 2 | -9 | 8 | -4 | -4 |
| Cash from Investing Activity | -1 | -3 | -2 | -1 | 1 | -6 | 0 | -4 |
| Cash from Financing Activity | 4 | 0 | 7 | -1 | 8 | -2 | 4 | 9 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Free Cash Flow | -4 | 0 | -8 | 1 | -9 | 2 | -4 | -8 |
| CFO/OP | -225 | 177 | -268 | 41 | -206 | 185 | -31 | -37 |

### Ratios

| Item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 111 | 153 | 132 | 215 | 192 | 197 | 155 | 148 |
| Inventory Days | 21 | 52 | 72 | 212 | 130 | 149 | 128 | 110 |
| Days Payable | 18 | 122 | 58 | 218 | 76 | 92 | 98 | 93 |
| Cash Conversion Cycle | 115 | 83 | 146 | 208 | 246 | 254 | 186 | 165 |
| Working Capital Days | 62 | 7 | 74 | 117 | 221 | 181 | 124 | 103 |
| ROCE % | — | 12 | 10 | 23 | 15 | 11 | 16 | 18 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% | 67.47% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 27.69% | 29.9% | 28.48% | 28.8% | 28.06% | 28.37% | 28.77% | 28.95% | 28.88% | 28.54% | 28.49% | 28.31% |
| Others | 4.84% | 2.64% | 4.06% | 3.73% | 4.47% | 4.16% | 3.76% | 3.58% | 3.66% | 3.99% | 4.04% | 4.22% |
| No. of Shareholders | 1260 | 921 | 873 | 832 | 825 | 966 | 997 | 1022 | 998 | 991 | 971 | 943 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 3 / 6 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 10.19 | Buy |
| EMA (10) | 10.34 | Buy |
| SMA (20) | 11.05 | Sell |
| EMA (20) | 10.79 | Sell |
| SMA (50) | 11.23 | Sell |
| EMA (50) | 10.97 | Sell |
| SMA (100) | 10.31 | Buy |
| EMA (100) | 10.85 | Sell |
| SMA (200) | 10.85 | Sell |
| EMA (200) | 11.84 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 46.32 | Neutral |
| MACD (12,26,9) | -0.49 | Sell |
| Stochastic (14,3,3) | 26.1 | Neutral |
| ADX (14) | 24.38 | Neutral |
| Williams %R (14) | -41.18 | Neutral |
| ATR (14) | 0.49 | High Volatility |
| ROC (12) | -2.29 | Sell |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 44.3 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 5 June 2026 - Jfl Life Sciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) … | [Disclosure under SEBI Takeover Regulations 5 June 2026 - Jfl Life Sciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) …](https://nsearchives.nseindia.com/corporate/team_bbodade_22042026165154_JFLLIFE.zip) |
| 5 Jun - SMIRAL ASHWINKUMAR PATEL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, … | [Disclosure under SEBI Takeover Regulations 5 Jun - SMIRAL ASHWINKUMAR PATEL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …](https://nsearchives.nseindia.com/corporate/team_bbodade_22042026155941_JFLLIFE.pdf) |
| 5 January 2026 - Certificate under Reg 74(5) by KFIN for quarter Oct 1–Dec 31, 2025. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 5 January 2026 - Certificate under Reg 74(5) by KFIN for quarter Oct 1–Dec 31, 2025.](https://nsearchives.nseindia.com/corporate/JFL_05012026201732_JFL_dp_certificate_dec_2025.pdf) |
| 4 March 2026 - Record date March 10, 2026 for 1:1 fully paid rights issue to shareholders. | [Record Date 4 March 2026 - Record date March 10, 2026 for 1:1 fully paid rights issue to shareholders.](https://nsearchives.nseindia.com/corporate/JFL_04032026155649_JFL_Record_Date_Intimation_04-03-2026_Signed.pdf) |
| 4 March 2026 - Approves 1:1 rights issue of 3,29,95,323 shares at Rs10; opens Mar 16, closes Mar 24, 2026. | [Rights Issue 4 March 2026 - Approves 1:1 rights issue of 3,29,95,323 shares at Rs10; opens Mar 16, closes Mar 24, 2026.](https://nsearchives.nseindia.com/corporate/JFL_04032026155326_JFL_Outcome_of_BM_04-03-2026_Signed.pdf) |
| 4 March 2026 - 1:1 rights issue of 3,29,95,323 shares at Rs10, raising Rs32.9953 crore; opens 16–24 Mar 2026. | [Updates 4 March 2026 - 1:1 rights issue of 3,29,95,323 shares at Rs10, raising Rs32.9953 crore; opens 16–24 Mar 2026.](https://nsearchives.nseindia.com/corporate/JFL_04032026160341_JFL_Outcome_of_BM_04-03-2026_Signed.pdf) |
| 4 April 2026 - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 4 April 2026 - Submitted Regulation 74(5) certificate for quarter ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/JFL_04042026170521_JFL_74_5__DP_March_2026.pdf) |
| 31 Jul - Integrated Annual Report FY2025-26 and AGM notice for August 25, 2026; director reappointments proposed. | [Shareholders meeting 31 Jul - Integrated Annual Report FY2025-26 and AGM notice for August 25, 2026; director reappointments proposed.](https://nsearchives.nseindia.com/corporate/JFL_31072026163414_JFL_FINAL_ANNUAL_REPORT_WITH_COVRING_LETTER_SIGNED.pdf) |
| 30 May 2026 - Published audited financial results for quarter and year ended 31 March 2026 on 30 May 2026. | [Copy of Newspaper Publication 30 May 2026 - Published audited financial results for quarter and year ended 31 March 2026 on 30 May 2026.](https://nsearchives.nseindia.com/corporate/JFL_30052026123638_FINALNEWSPAPERADVT30052026signed.pdf) |
| 3 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 3 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026.](https://nsearchives.nseindia.com/corporate/JFL_03072026150316_74_5__JUNE_2026_Signed.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30100_JFLLIFE_2025_2026_A_5859060_31072026163813.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28225_JFLLIFE_2024_2025_A_7035743_02092025211110.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25636_JFLLIFE_2023_2024_03092024224513.pdf) |
| from nse | [Annual Report 2023 from nse](https://archives.nseindia.com/annual_reports/SME_AR_23336_JFLLIFE_2022_2023_04092023113325_09042023120001.zip) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:38:08.165Z.